Clinical Trial

A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to learn how the study medicine called carbamazepine changes how the body processes the other study medicine called PF-07248144. The study will also look at the safety, tolerability, and how PF-07248144 is changed and removed from the body after taking PF-07248144 alone compared to when it is taken with carbamazepine. Carbamazepine can change how your body processes some medications so it may change the body's processing of PF-07248144. Multiple blood samples will be collected up to 8 days after each dose of PF-07248144 to determine how much PF-07248144 is in the blood at different times. This will help characterize the pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it) of PF-07248144 alone and when taken with carbamazepine.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-25.
Status change: Recruiting → Completed 2026-03-30
Trial Details
NCT Number NCT07198035
Lead Sponsor Pfizer
Conditions Healthy Adults
Enrollment 12 participants
Start Date 2025-09-18
Primary Completion 2025-12-17 (estimated)
Study Completion 2026-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-03